Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 22, 2015 08:00 ET | Source: Egalet Corporation

Egalet Announces Positive Top-Line Results From Oral Human Abuse Liability Study of Abuse-Deterrent Morphine, Egalet-001

WAYNE, Pa., Jan. 22, 2015 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet") today announced positive results from a Category 3 human abuse liability (HAL) study of Egalet-001, an...
January 09, 2015 08:00 ET | Source: Egalet Corporation

Egalet Appoints Deanne F. Melloy as Chief Commercial Officer

WAYNE, Pa., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet") today announced the appointment of Deanne F. Melloy as chief commercial officer (CCO). Ms. Melloy will be...
January 08, 2015 08:14 ET | Source: Egalet Corporation

Egalet Acquires/Licenses Two Innovative Approved Pain Products

--Transactions transform Egalet into a commercial specialty pharmaceutical company paving the way for commercialization of late-stage pipeline of abuse-deterrent opioids -- -- Company has...
November 05, 2014 08:30 ET | Source: Egalet Corporation

Egalet to Present at the Stifel 2014 Healthcare Conference on November 18

WAYNE, Pa., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet") today announced that Bob Radie, president and chief executive officer, is scheduled to present at the Stifel...
September 23, 2014 16:00 ET | Source: Egalet Corporation

Egalet Announces Update on Clinical Development Plan for Abuse-Deterrent Morphine Egalet-001

WAYNE, Pa., Sept. 23, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) (Egalet) today announced an update to the clinical development plan for Egalet-001, an abuse-deterrent,...
September 11, 2014 08:00 ET | Source: Egalet Corporation

Egalet Announces Issuance of U.S. Patents Covering Guardian(TM) Technology and Product Candidates

WAYNE, Pa., Sept. 11, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet") today announced the issuance of patents by the U.S. Patent and Trademark Office (USPTO) covering Egalet's...
September 04, 2014 08:30 ET | Source: Egalet Corporation

Egalet to Present Data from Abuse-Deterrence Studies at PAINWeek 2014 in Las Vegas

LAS VEGAS, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet") announces data presentations on Egalet-001, an abuse-deterrent, extended-release, oral morphine product...
August 18, 2014 08:00 ET | Source: Egalet Corporation

Egalet Announces Successful End-of-Phase 2 Meeting With the FDA for Egalet-002

WAYNE, Pa., Aug. 18, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet") today announced the completion of a successful end-of-Phase 2 meeting with the U.S. Food and Drug...
August 06, 2014 06:00 ET | Source: Egalet Corporation

Egalet Announces Topline Results From Bioequivalence Studies of Abuse-Deterrent Morphine, Egalet-001

WAYNE, Penn., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet") today announced that we have top-line results from two of the three bioequivalence (BE) studies of...
July 30, 2014 08:30 ET | Source: Egalet Corporation

Egalet to Present at the Canaccord Genuity Growth Conference on August 13

WAYNE, Pa., July 30, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet") today announced that Bob Radie, president and chief executive officer, is scheduled to present at the...